Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia by Gratwohl, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23015
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
British Journal of Haematology, 1996, 95, 4 9 4 -5 0 01
Splenic irradiation before bone marrow transplantation 
for chronic mveloid leukaemia
A .  G r a t w o h l ,  J. H e r m a n s ,  A .  v .  B i e z e n ,  W .  A r c e s e ,  L. D e b u s s c h e r ,  P .  E r n s t ,  A .  F e r r a n t ,  F .  F r a s s o n i ,
G. G a h r t o n ,  A. I r i o n d o ,  H. J. K o l b ,  H. L i n k ,  D. N i e d e r w i e s e r ,  T. R u u t u ,  A. S c h a t t e n b e r g ,  N. S c h m i t z ,
W. S i e g e r t ,  A .  T o r r e s - G o m e z ,  J. P. V e r n a n t ,  F. E. Z w a a n  a n d  J. A p p e r l e y
for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 
Received 14 Mau 1996; accepted for publication 15 August 1996
Summary. A total of 229 patients with chronic myeloid 
leukaemia (CML) in chronic phase were randomized 
between 1986 and 19 9 0 to receive or not receive additional 
splenic irradiation as part of their conditioning prior to bone 
marrow transplantation (BMT). Both groups, 115 patients 
with and 114 patients without splenic irradiation, were very 
similar regarding distribution of age, sex, donor/recipient sex 
combination, conditioning, graft-versus-host disease (GvHD) 
prevention method and blood counts at diagnosis or prior to 
transplant. 135 patients (59%) are alive as of October 1995
■
with a minimum follow-up of 5 years. 52 patients have 
relapsed (23%), 26 patients in the irradiated, 26 patients in 
the non-irradiated group (n.s.) with a relapse incidence at 6 
years of 28%. The main risk factor for relapse was T-cell 
depletion as the method for GvHD prevention, and an 
elevated basophil count in the peripheral blood prior to 
transplant. Relapse incidence between patients with or 
without splenic irradiation was no different in patients at
Bone marrow transplantation (BMT) is the treatment of choice 
for young patients with CML who have an HLA-identical 
sibling donor (Armitage, 1994; Silvert, 1990; Thomas & 
Clift, 1989). More than 50% of patients are alive more than 
10 years after transplant (Armitage, 1994; van Rhee et al, 
1996; McGlave, 1990; Gratwohl et al, 1993; Goldman et al, 
1986) and CML is the most frequent single indication for 
BMT (Gratwohl et al, 1996). The treatment has been 
standardized, and risks of the procedure have been defined. 
However, treatment-related mortality and relapse incidence 
are still a matter of concern and little progress has been made 
with the prevention of relapse (Gratwohl et al, 1995a).
When BMT was introduced as a therapeutic modality for 
CML, splenectomy as a debulking procedure was thought
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high risk for relapse, e.g. patients transplanted with T-cell- 
depleted marrows (P =  n.s.) and in patients with low risk for 
relapse, e.g. patients transplanted with non-T-cell-depleted 
transplants and basophil counts < 3% prior to transplant 
(P =  n.s.). However, relapse incidence differed significantly in 
patients with non-T-cell-depleted transplants and high 
basophil counts (> 3% basophils in peripheral blood). In 
this patient group, relapse incidence was 11% at 6 years 
with splenic irradiation but 32% in the non-irradiated group 
(P=Q-05). Transplant-related mortality was similar 
whether patients received splenic irradiation or not. This 
study suggests an advantage in splenic irradiation prior to 
transplantation for CML in this subgroup of patients and 
illustrates the need for tailored therapy.
Keywords: splenic irradiation, bone marrow transplanta­
tion, chronic myeloid leukaemia, relapse.
essential (Clift etal, 1982; Goldman et al, 1982; Speck et ah 
1982, 1984). A retrospective analysis comparing splenect­
omy, splenic irradiation and no splenic treatment showed no 
differences and corrected prevailing opinions; it formed the 
basis for the present prospective randomized trial (Gratwohl 
et al, 1985). A first analysis with a short observation time 
failed to reveal a difference (Gratwohl et ah 1992, 1994). 
Splenic treatment has therefore been largely abandoned in 
the last few years. An update of the prospective randomized 
study with a minimum follow-up of 5 years now shows that 
splenic irradiation needs to be reconsidered; it is likely to be 
of benefit for relapse prevention in a specific cohort of 
patients, as outlined below.
i
PATIENTS AND METHODS
Study design. In a prospective controlled study patients
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were randomized to receive or not receive splenic irradiation 
during conditioning for BMT. Randomization was performed 
centrally for each individual participating team (see 
Appendix) in blocks of six patients. They were stratified by 
age ( <25 years, Ss 25 years) and by whether or not T-cell 
depletion was used as a way of preventing GvHD. Each 
patient was registered at the time of randomization with an 
on-study form. The study was opened in May 1986 and closed 
in May 1990. Patient status was updated as of October 1995. 
Thus the minimum follow up of all patients was 5 years.
Inclusion criteria. The trial population consisted of patients 
with CML in first chronic phase awaiting a BMT from an 
HLA-identical sibling donor. Patients at another stage of the 
disease, those without an HLA-identical sibling donor and 
those with prior splenectomy or splenic irradiation were 
excluded. The criteria for chronic, accelerated or blastic 
phase of the disease were applied according to the definitions 
laid down by the International Bone Marrow Transplant 
Registry (Speck et al, 1984). Excluded from chronic phase 
are patients fulfilling one or more of the following criteria: 
(1) white cell counts (WBC) difficult to control with 
conventional regimens of busulphan and hydroxyurea; (2) 
rapid doubling of WBC (^  5 d); (3) >  10% blasts in blood or 
marrow; (4) ^  20% blasts plus promyelocytes in blood or 
marrow; (5) ^ 20% basophils plus eosinophils in blood; (6) 
anaemia or thrombocytopenia unresponsive to busulphan/ 
hydroxyurea; (7) persistent thrombocytosis; (8) new cyto­
genetic abnormalities; (9) increasing splenomegaly; (10) 
development of chloromas or myelofibrosis, and (11) the 
patient was in a second (or subsequent) chronic phase after 
blast crisis. The blast phase was characterized by > 30% 
blasts plus promyelocytes in the blood or bone marrow.
Patient population. Details of the 229 patients, 147 males 
and 81 females with a median age of 33 years (8-52 years) 
included in the analysis are listed in Table I. 115 were 
randomized to receive, 114 not to receive splenic irradiation. 
They were treated in 30 European institutions as listed in the 
Appendix.
Treatment regimen. Three splenic irradiation options were 
offered to the participating teams: 10 Gy as a single dose (52 
patients), two doses of 5 Gy (28 patients) or three doses of 3-3 
Gy ( 35 patients). Splenic irradiation had to be given within 
14 d preceding transplant. Dose rate, field size and 
radiation were determined by the treating centre.
The transplant conditioning regimen (92% with a regi-
<
men including total body irradiation), GvHD prophylaxis 
method (Table I) and supportive care during the transplant 
period were applied according to the local protocol of each 
centre. The protocol was approved by the Ethics Committee 
of the Kantonsspital Basel.
Collection of data and statistical analysis. At the time of 
randomization, information was obtained on patient age, 
sex, disease status, peripheral blood values, spleen size and 
planned therapy. More extensive patient information, data 
on donor, transplant procedure, conditioning, GvHD pre­
vention method, recovery of peripheral blood values and 
final outcome were obtained by the Chronic Leukaemia 
Working party using the EBMT data base management 
system (Korver ei ai, 1988).
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Table I. Population characteristics.
Splenic Irradiationt
Yes No
Total patients 115 114
Age
Median (years) 33 32
Range (years) 8 - 5 2 9 -5 0
< 2 5  years 22 38
>  25 years 93 96
Sex
Male 70 77
Female 45 37
Donor-recipient sex combination*
Female donor/male recipient 28 34
Other 85 79
Time interval from diagnosis to transplant
< 1 2  months 66 61
> 1 2  months 48 52
1
GvHD prophylaxis 115 114
Without T-cell depletion 84 87
Cyclosporin 22 18
Cyclosporin +  Mtx 4 9 54
Other combinations 13 15
With T-cell depletion 31 27
T-cell depletion alone 9 3
T-cell depletion combined 22 24
Basophils at BMT*
<  3% 59 59
>  3% 54 53
* Three or four missing patients not included.
+ No difference between groups by chi-square or Mann-Whltney
Study endpoints, survival, leukaemia-free survival, relapse 
incidence and transplant-related mortality were calculated 
as previously described (Clift et al, 1989). Relapse was 
defined as clinical relapse with obvious signs of disease in 
peripheral blood smears and/or bone marrow.
The statistical ance of percentage
between groups were determined with the Chi-square test
or exact test. The of OL'
continuous measurements was compared with the Mann- 
Whitney test. The distribution of time span of events was 
made with the log rank test. For multivariate analysis Cox's 
proportional hazard model was applied. All analyses were 
based on an intentlon-to-treat randomization approach. All 
P values were two-sided if applicable.
RESULTS
Comparison between the two groups
Known risk factors for outcome after transplantation for
such as age,. sex, donor sex, sex
combination, were no different between the two groups
©  1996 Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 -5 0 0
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(Table I). The same holds true for disease status at diagnosis 
or at time of transplant, haemoglobin level, total white blood 
cell count, percentage of blast cells, percentage of basophils, 
platelet count, spleen size and time from diagnosis to 
transplant. There is a slightly higher, but not significant, 
representation of patients with poor risk factors (female 
donor, male recipient; age > 2 5  years, and interval from
diagnosis to transplant >  12 months) in the group without
splenic irradiation. These factors were considered in the 
multivariate analysis. The Sokal index was not determined
,
at the time of study initiation and could not be reconstructed 
retrospectively, since spleen size was not assessed uniformly. 
The majority of teams reported only clinical findings 
(spleen not palpable) or number of fingers below costal 
margin for patients randomized to receive no splenic
irradiation, and in addition to these findings reported
i
computed tomography or ultrasound measurements for
«
patients with splenic irradiation (Gratwohl et al, 1992). 
This difference in reporting was recognized only after 
termination of the study and explains why spleen size 
could not be further analysed. The proportion of patients 
with ‘normal’ or ‘very large’ spleens showed no difference in 
the two groups.
100
75
5 0 -
2 5 -
0
0
SURVIVAL
SPLEEN IRR.
YES (N = 115) 
NO (N = 114)
TRM
YES
NO
NO
YES
12 24 36 
MONTHS
48 60 72
Fig 1. Survival and transplant-related mortality (TRM) of patients 
transplanted for CML with (yes) or without (no) splenic irradiation 
during conditioning.
Table II. Influence of splenic irradiation on relapse incidence.
(A) Main subgroups
At 6 years
i
No. 
at risk
Relapse incidence
N % (SE) P
Splenic irradiation 
Yes 115 42 28 (5)
No 114 33 30 (5) 0-4.1
T-cell depletion
No 171 60 21 (4)
Yes 58 15 53 (8) < 0 -0 0 1
Basophils at BMT
< 3% 118 35 25 (5)
>  3% 107 39 33 (5) 0-16
Missing 4
(B) Combined subgroups
T-cell
depletion
No
Yes
Basophils 
at BMT (%)
<  3
> 3
<  3
^  3
Splenic irradiation
No. at start
45
38
14
1 6
Relapse incidence 
at 6 years (%)
24
11
40
62
No splenic irradiation
No. at start
47
38
12
15
Relapse incidence 
at 6 years (%)
15
32
48
5 8
P
0-39
0-05
0*64
0-93
©  1996  Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 - 5 0 0
Splenic Irradiation in BMT for CML 497
RELAPSE RISK
100 -
75
50
25
0
1
YES(N = 45)
RELAPSE RISK MONTHS
100
75
50-
YES(N= 14)
25
0
0 12 24 36 48 60 72 84
MONTHS
RELAPSE RISK
100 -
75
50 —
25
0
T-cell Bas. 
dep. BMT
1 no <3%
2 no > =3%
3 yes <3%
4 yes > = 3%
r
r
RELAPSE RISK
100-
7 5 -
NO(N =12) 5°
2 5 -
0
0 12 24 36 48 60
NOIN »38)
38)
MONTHS
YES(N = 16)
NO(N= 15)
72 84
MONTHS
Fig 2. Relapse incidence of patients transplanted for CML with ( yes) or without (no) splenic ir on T-cell
depletion (T-cell dep.) and basophil counts in the peripheral blood prior to transplant (< 3% or >  3%).
Treatment
All 115 patients randomized for splenic irradiation were 
subjected to this treatment as follows. T-cell depletion, was 
applied in 58 patients (31 with and 27 without splenic 
irradiation), whilst 1.71 patients had no T-cell depletion (84 
with and 8 7 without splenic irradiation). Cyclosporin or the 
combination of cyclosporin and methotrexate for GvHD 
prevention was given to 143 patients, 28 received another 
combination. The different methods were evenly distributed 
between the two groups (Table I).
Survival and relapse
As of October 1995, 135 patients were alive, 71 in the 
splenic irradiation group and 64 in the non-irradiated group. 
The survival at 6 years was 62% v 57% (P =  0-70; Fig 1). 
103 patients were alive without relapse, 52 with and 51 
without splenic irradiation. A total of 94 patients died, 74 
patients died without relapse and were considered as 
transplant-related deaths (37 with and 37 without splenic 
irradiation); transplant-related mortality (TRM) at 6 years 
was 32% v 33% (P =  0-92; Fig 1).
Clinical relapses occurred in 52 patients (30%), 26 in each 
group; the relapse rate at 6 years is 28% in the irradiated
group and 30% in the non-irradiated group ( P =  041), It is 
well known that the relapse rate in patients transplanted for 
CML is strongly influenced by whether or not patients are 
transplanted with T-cell-depleted bone marrow (McGlave, 
1990). In a previous analysis by the EBMT we 
established that a basophil count in the peripheral blood at
Table III. Results of
■M M «*
Relative risk for relapse
(<*• .  .  *  A I I I '  I .  b I ■ ’  . i \  ,  , . y v ;  < ' « • . ..............M,, . 1  » L .  •
Splenic irradiation RR Cl
I.“  . 1 '  . . |  , 1  l , i ,  . H i l - ' J  . 1 4 .  . . .  . ■ j  f, :
No
Yes
<  3 %  
2* 3 %
<  3 %  
S* 3 %
1-00
2-85
2-29
1*03
((>88“ 9‘2 3 )
((>67-7' 
(0-25-4*27)
:e with spleen irradiationCox regression model 
and basophil counts at BMT as risk 
sex combination and interval from diagnosis to BMT. 
restricted to non T-cell-depleted patients (N = 171).
(Q 1996 Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 -5 0 0
498 A. Gratwohl et al
time of transplant of ^ 3% is a risk factor for relapse 
(Gratwohl et al, 1994). Relapse incidence was therefore 
compared between both treatment groups, with special 
emphasis on with or without T-cell depletion and on 
basophil count below or above 3%. The relapse rates are 
listed in Tables IIA and IIB, and illustrated in Fig 2. The 
impact of T-cell depletion on relapse was confirmed and 
relapse incidence remained higher in patients with increased 
basophil counts (Table IIA), although not significant 
(P =  016). When comparing splenic irradiation with no 
splenic irradiation taking into account the two risk factors 
(Table IIB and Fig 2), splenic irradiation had no extra effect 
on a high relapse incidence as soon as T-cell depletion was 
involved. Without T-cell depletion and a low basophil level, 
splenic irradiation again has no extra effect. But, for the 
group without T-cell depletion and basophils at a risk level 
(>  3 %), it appeared that splenic irradiation played some role 
in relapse prevention: at 6 years relapse incidence was 11% v 
32% (P =  0*05).
In view of the possible consequences for clinical practice, 
we added a multivariate Cox regression analysis on the 
relapse incidence, restricted to non-T-cell-depleted patients. 
The main interest was on splenic irradiation (yes or no), 
basophil counts (low or high) and the interaction between 
these two variables. Adjustments were made for age, sex, sex 
combination and interval from diagnosis to transplant. 
The analysis showed a significant interaction (P =  003)  
between splenic irradiation and basophil counts, confirming 
that splenic irradiation in the case of a high basophil level 
could be beneficial for preventing relapses. The resulting 
relative risks are shown in Table III. Due to the interaction
Tollemar et al, 1989; Bostrom et al, 1990: Kahls et al, 1995). 
These small benefits are not reflected in better survival. 
Potential benefits are offset by an increased risk of acute 
GvHD, a higher risk of deep fungal infections and late gram- 
positive bacterial sepsis (Ringden & Nilsson, 1993; Michallet 
et al, 1991; Tollemar et al, 1989: Bostrom et al, 1990). For 
reasons of feasibility, splenectomy has never been evaluated 
in a prospective controlled study.
Splenic irradiation offers a theoretical advantage over 
splenectomy. It should achieve the same goals without the 
need for surgery, although it can cause limited kidney and 
colon damage within the actual irradiation area (Gratwohl 
et al, 1994). One patient in this series died 18 years post­
transplant secondary to complications to radiation-induced 
colitis; no autopsy was performed.
A suspected better survival in a retrospective analysis in 
1985 formed the basis for the present randomized trial 
which was conducted between 1986 and 1990 (Gratwohl 
et al, 1985). Two interim analyses were made with a 
minimal follow-up of 5 months and 2 years, respectively 
(Gratwohl et al, 1992, 1994). They were published and 
produced a negative conclusion. No benefit could be shown 
between the two treatment groups. In view of the potential 
damage to adjacent organs, splenic irradiation was no 
longer recommended as part of the preparative regimen. The 
present update indicates that this statement needs to be 
modified.
The two cohorts were followed with annual updates. The 
figures for transplant-related mortality overlapped, but a 
slight trend for better survival appeared for the patients 
given splenic irradiation, and slightly fewer relapses
effects the ratio of the relative risks is reversed (irradiation occurred in the treatment group. In the meantime, two
yes versus no) for basophils ^ 3% compared to < 3%. factors became clear, both unknown at the start of the study.
Graft-versus-host disease
Patients with T-cell depletion undergoing BMT for CML have 
a high relapse risk. Furthermore, chronic phase does not
Incidence of acute and chronic GvHD have been previously describe a homogenous patient population. It includes
analysed in detail for this study cohort. 42% of all patients patients with minimal disease as well as with
had ^  grade II acute GvHD, 44% in the group with and 40% impending acceleration. Time from diagnosis to transplant
in the group without splenic irradition. Acute GvHD was and features of late chronic phase, such as a high basophil
higher in older patients, in those without T-cell depletion 
and in male patients with a female donor, as previously
count, influence outcome.
A subset analysis of the patients to T-cell
reported (Gratwohl et al, 1995a). depletion or not and considering basophil counts at BMT,
provided a better insight. Patients with T-cell depletion lack
DISCUSSION
Reduction of tumour load prior to curative therapy is 
thought to be important for most treatment strategies in 
oncology. Splenectomy seemed to be the best approach to 
achieve debulking and removal of leukaemic cells in patients 
with CML when BMT was introduced (Clift et al, 1982; 
Goldman et al, 1982; Speck et al, 1982, 1984). However, 
several retrospective studies have now shown that it fails to 
reduce rejection or relapse and does not improve survival 
(Gratwohl et al, 1985, 1992, 1994; Clift etal, 1991). It may 
be beneficial in individual patients with massive spleno­
megaly for avoiding delayed engraftment and improving 
pancytopenia post transplant (Helenglass et al, 1990; Banaji 
et al, 1986; Martino et al, 1994; von Bueltzingsloewen et al, 
1994; Ringden & Nilsson, 1993; Michallet et al, 1991;
graft-versus-leukaemia reactivity. Additional splenic irra­
diation does not sufficiently compensate, and no difference 
can be found in this group of patients with a high relapse 
risk. Similarly, in patients with low relapse risk, e.g. those 
with non-T-cell-depleted BMT and early disease, no effect of 
additional splenic irradiation can be documented. Differ­
ences emerge in the group of intermediate risk: non-T-cell- 
depleted transplants and elevated basophil counts. Relapse 
incidence is reduced and delayed by splenic irradiation. 
These findings make biological sense and are easy to 
conceive. Splenic irradiation might act as a local additional 
conditioning devoid of systemic toxicity and tip the balance 
in this intermediate-risk group.
The present study suggests that patients with elevated 
basophil counts at time of transplant represent a group of 
patients probably at higher risk for relapse. For
©  1996 Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 -5 0 0
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patients, splenic irradiation might offer an advantage. It is 
associated with little systemic toxicity and, as shown in this 
study, compared to intensified conditioning (Clift et al, 1991) 
has no influence on transplant-related mortality. In contrast 
to splenectomy (Kahls etal, 1995), it should be reconsidered 
in BMT treatment schedules for patients with CML and signs 
of more advanced disease.
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APPENDIX
List of participating institutions
Basel: Kantonsspital Basel (B. Speck, A. Gratwohl); Berlin: 
Universitätsklinikum Rudolf Virchow (W. Siegert); Birming­
ham: Queen Elizabeth Hospital, Birmingham (I. M. Frank­
lin); Brussels: Institut J. Bordet (L. Debusscher), Hôpital 
Universitaire St Luc (A. Fermat); Caen: Centre hospitalier 
(X. Troussard); Copenhagen: University Hospital (N. Jacob­
sen); Cordoba: Hospital Reina Sofia (A. Torres-Gomez); 
Créteil: Hôpital H. Mondor (J.-P. Vernant); Dublin: St 
James’ Hosputal (S. R. McCann); Edinburgh: Royal Infirmary 
(A. C. Parker); Genova: Ospedale San Martino (A. Baci- 
galupo, F. Frassoni); Hanover: Medizinische Hochschule 
(H. Link); Helsinki: University of Helsinki (T. Ruutu, 
L. Violin); Huddinge: Karolinska Institute (B. Lössqvist, 
G. Gahrton, 0. Ringden); Innsbruck: Universitätsklinik für 
Innere Medizin (D. Niederwieser) ; Kiel: Christian Albrechts- 
Universität (N. Schmitz); Leiden: University Hospital 
(F. E. Zwaan, W. Fibbe); Lisbon: Inst. Portugues Oncologia 
(M. Abecasis); London: Harley Street Clinic (P. J. Gravett); 
Royal Marsden Hospital (R. Powles, G. Helenglass), Royal 
Free Hospital (H. G. Prentice); Munich: Ludwig Maximilians- 
Universität (H. J. Kolb); Nijmegen: Sint Radboudziekenhuis 
(T. de Witte, T. Schattenberg); Paris: Centre hospitalier St 
Antoine (N. C. Gorin); Pessac: Centre hospitalier ( J. Reiffers); 
Riyadh: King Faisal Hospital (P. Ernst); Rome: Università 
degli Studi di Roma ‘La Sapienza’ (W. Arcese); Santander:
nacional ‘Marques de Valdecilla’ (A. Iriondo); 
Vienna: Allgemeines Krankenhaus der Stadt Wien 
(W. Hinterberger).
REFERENCES
Armitage, J.O. (1994) Bone marrow transplantation. New England 
Journal of Medicine, 330, 8 2 7 -8 3 8 .
Banaji, M., Bearman, S.I., Buckner, C.D., Clift, R.A., Bensinger, W.S., 
Petersen, F.B., Slichter, S.J., McGuffin, R.W., Sanders, J.E. & 
Stewart, P.S. (1986) The effect of splenectomy on engraftment 
and platelet transfusion requirements in patients with chronic 
myelogenous leukemia undergoing marrow transplantation. 
American Journal of Hematology, 22, 2 7 5 -2 8 3 .
Bostrom, L., Ringden, O., Jacobsen, N., Zwaan, F. & Nilsson, B., for 
the Leukemia Working Party of the European Bone Marrow 
Transplantation Group (1990) A European multi-center study of
chronic graft-versus-host disease: the role of cytomegalovirus 
serology in recipients and donors, acute graft-versus-host disease 
and splenectomy. Transplantation, 49, 1100-1105.
Clift, R.A., Buckner, C.D., Appelbaum, F.R., Bryant, E., Bearman, 
S.I., Petersen, F.B., Fisher, L.D., Anasettic, C., Beatty, P., 
Bensinger, W.I., Doney, K., Hill, R.S., McDonald, G.B., Martin, 
P., Meyers, J., Sanders, J., Singer, J., Stewart, P., Sullivan, K.M., 
Witherspoon, R., Storb, R., Hansen, J.A. & Thomas, E.D. (1991) 
Allogeneic marrow transplantation in patients with chronic 
myeloid leukemia in the chronic phase: a randomized trial of 
two irradiation regimens. Blood, 77, 1660-1665.
Clift, R.A., Buckner, C.D., Thomas, E.D., Molina, L., Peissel, B., 
Maranchtni, D., Reiffers, J., Chabannon, C., Gaspard, M.H., 
Stoppa, A.M., Blaise, D., Merit, G„ I-Iollard, D., Carcassone, Y., 
Bronstet, A. & Demongeot, J. (1982) Treatment of chronic 
granulocytic leukaemia in chronic phase by allogeneic marrow 
transplantation. Lancet, ii, 621-622 ,
Clift, R.A., Goldman, J,, Gratwohl, A. & Horowitz, M. (1989) 
Proposals for standardized reporting of results of bone marrow 
transplantation for leukemia. Bone Marrow Transplantation, 4, 
4 4 5 —448.
Goldman, J.M., Apperley, J.F., Jones, L., Marcus, R„ Goolden, A.W., 
Batchelor, R., Hale, G., Waldmann, H„ Reid, C.D., Hows, J., 
Gordon-Smith, E., Catovsky, D. & Galton, D.A.G. (1986) Bone 
marrow transplantation for patients with chronic myeloid 
leukemia. New England Journal of Medicine, 314, 202-207 .
Goldman, J.M., Baughan, A.S.J., McCarthy, D.M., Worsley, A.M., 
Hows, J.M., Gordon-Smith, E.C., Catovsky, D., Batchelor, J.R., 
Goolden, A.W, & Galton, D.A.G. (1982) Marrow transplantation 
for patients in chronic phase of chronic granulocytic leukaemia. 
Lancet, ii, 6 2 3 -6 2 5 .
Gratwohl, A., Gluckman, E., Goldman, J. & Zwaan, F. (1985) 
Effect of splenectomy before bone marrow transplantation on 
survival in chronic granulocytic leukaemia. Lancet, ii, 1290-  
1291.
Gratwohl, A., Hermans, J., Apperley, J,, Arcese, W„ Bacigalupo, A„ 
Bandini, G., dl Bartolomeo, P., Boogaerts, M., Bosl, A., Carreras, 
E., Devergie, A., Ferrant, A., Fibbe, W.E., Frassoni, F„ Gahrton, G., 
Goldman, J,, Iriondo, A., Jacobsen, N., Kolb, H.J., Link, II,, 
Michallet, M., Prentice, H.G., Reiffers, J., van Rhee, F., Ruutu, T., 
Schwaighofer, H., Vernant, J.P., de Witte, Ï . & Niederwieser, D., 
for the Working Party Chronic Leukemia of the EBMT (1995a) 
Acute graft-versus-host disease: grade and outcome in patients 
with chronic myelogeneous leukemia. Blood, 86, 813-818 .
Gratwohl, A., Hermans, J. & Baldomero, H. (1996) Hematopoietic 
precursor cell transplants in Europe: activity in 1994. Bone 
Marrow Transplantation, 17 , 137-148 .
Gratwohl, A., Hermans, J., v. Biezen, A., Arcese, W., de Witte, T., 
Debusscher, L„ Ernst, E„ Ferrant, A., Frassoni, F., Gahrton, G„
Iriondo, A., Kolb, II.)., Link, IL, T
Schmitz, N„ Siegert, W., Torres-Gomez, A., Vernant, J.P. & Zwaan 
F.E. (1992) No advantage for patients who receive s 
irradiation before bone marrow transplantation for chronic 
myeloid leukemia: results of a prospective randomized study. 
Bone Marrow Transplantation, 10, 147-152.
Gratwohl, A., Hermans, J., v. Biezen, A., Arcese, W., de Witte, T„ 
Debusscher, L., Ernst, P., Ferrant, A., Frassoni, F., Gahrton, G„ 
Iriondo, A., Kolb, H.J., Link, H., Niederwieser, D„ Ruutu, T., 
Schmitz, N., Siegert, W., Torres-Gomez, A., Vernant, J.P. & Zwaan, 
F.E. (1994) Splenic irradiation before bone marrow trans­
plantation for chronic myeloid leukemia: update of a prospect­
ive randomized study. Leukemia and Lymphoma, 7, (Suppl. 1), 
2 2 7 -2 3 1 .
Gratwohl, A., Hermans, J., Niederwieser, I)., Frassoni, P., Arcese, W„ 
Gahrton, G., Bandini, G„ Carreras, E., Vernant, J.P., Bosi, A,,
©  1996 Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 -5 0 0
500 A. Gratwohl et al
de Witte, T., Fibbe, W.E., Zwaan, F., Michallet, M., Ruutu, T., 
Devergie, A., Iriondo, A., Apperley, ]., Reiffers, J., Speck, B. & 
Goldman. J., for the Chronic Leukemia Working Party of the 
European Group for Bone Marrow Transplantation (.1993) Bone 
marrow transplantation for chronic myelogenous leukemia: long­
term effects. Bone. Marrow Transplantation, 12, 509.
Gratwohl, A., Hermans, J., Pearce, R., Gorin, N.C., Apperley, J., de 
Witte, T., Gahrton, G., Schmitz, N., Philip, T., Rosti, G., Goldstone, 
A., Ernst, P. & Bacigalupo, A., for the European Group for Blood and 
Marrow Transplantation (EBMT) (1995b) Hematopoietic precursor 
cell transplants: main risk factors. Blood, 86, (Suppl. 1), 618a.
Helenglass, G., Trealeven, J., Parikh, P., Aboud, H., Smith, C. & 
Powles, R.L. (1990) Delayed engraftment associated with 
splenomegaly in patients undergoing bone marrow transplan­
tation for chronic myeloid leukemia. Bone Marrow 
Transplantation, 5, 2 4 7 -2 5 1 ,
Kahls, P., Schwarzinger, I., Anderson, G., Mori, M., Clift, R.A., Storb, 
R., Buckner, C.D., Appelbaum, F.R., Hansen, J.A. & Sullivan, IC.M. 
(1995) A retrospective analysis of the long-term effects of 
splenectomy on late infections, graft-versus-host disease, relapse 
and survival after allogeneic marrow transplantation for chronic 
myelogenous leukemia. Blood, 86, 2028-2031 .
Korver, K., Brand, R. & Zwaan, F, (1988) Introduction of the EBMT 
computer program. Bone Marrow Tratisplantation, 3, (Suppl. 1), 159.
Martino, R., Altes, A., Muniz-Diaz, E., Brunet, S., Sureda, A., 
Domingo-Albos, A. & Madoz, P. (1994) Reduced transfusion 
requirements in a splenectomized patient undergoing bone 
marrow transplantation. Acta Haematologica, 92, 167-168 .
McGlave, P. (1990) Bone marrow transplants in chronic myelo­
genous leukemia: an overview of determinants of survival. 
Seminars in Hematology, 2 7 , 2 3 -3 0 .
Michallet, M., Corront, B., Bosson, J.L., Doney, K., Fefer, A., Nelman, 
P.E., Singer, J„ Sanders, J., Stewart, P., Sullivan, K.M., Deeg, J. &
Storb, R. (1991) Role of splenectomy in incidence and severity of
study of 1573aase: aacute graft-versus- 
patients. Bone Marrow Transplantation, 8, 13 -17 .
Ringden, O. & Nilsson, B. (1993) Death by graft-versus-host disease 
is associated with HLA-mismatch, high recipient age, low marrow 
cell dose and splenectomy. Transplantation, 40, 39-43 .
Silvert, R.T. (1990) Chronic myeloid leukemia. Hematology/Oncology 
Clinics of North America, 4, 319-335.•
Speck, B., Bortin, M.M., Champlin, R., Goldman, J.M,, Herzig, R.H., 
McGlave, Ph.B., Messner, H.A., Weiner, R.S, & Rimm, A.A. 
(1984) Allogeneic bone marrow transplantation for chronic 
myelogenous leukaemia. Lancet, i, 665 -668 ,
Speck, B., Gratwohl, A., Nissen, C., Osterwalder, B., Müller, M., 
Bannert, P., Müller, H.J. & Jeannet, M. (1982) Allogeneic bone 
marrow transplantation for chronic granulocytic leukemia. Blut, 
45, 2 3 7 -2 4 2 .
Thomas, E.D. & Clift, R.A. (1989) Indications for marrow transplant­
ation in chronic myelogenous leukemia. Blood, 7, 86.1-864. 
Tollemar, J., Ringden, 0., Boström, L., Nilsson, B. & Sundberg, B. 
(1989) Variables predicting deep fungal infections in bone marrow 
transplant recipients. Bone Marrow Transplantation, 4, 635-641. 
van Rhee, F., Szydlo, R.M., Hermans, J., Niederwieser, D., Jacobsen, 
N., Frassoni, F., Arcese, W., Gahrton, G., Bandini, G., Carreras, E., 
Bacigalupo, A., de Witte, T., Kolb, H.J., Link, H., Michallet, M., 
Fibbe, W.E., Ruutu, T., Devergie, A., Iriondo, A., Reiffers, J,, 
Nielsen, J., Goldman, J.M., Apperley, J. & Gratwohl, A., for the 
Chronic Leukemia Working Party of the European Group for 
Blood and Marrow Transplantation (1996) (in press), 
von Bueltzingsloewen, A., Bordignoni, P., Dorveaux, Y., Witz, F., 
Schmitt, C., Chastagner, P. & Sommelet, D. (1994) Splenectomy 
may reverse pancytopenia occurring after allogeneic bone 
marrow transplantation. Bone Marrow Transplantation, 14, 339-  
340.
©  1996 Blackwell Science Ltd, British Journal of Haematology 95: 4 9 4 - 500
